However, for patients with unresectable
advanced NSCLC, there is still a need for new therapeutic strategies as the five-year survival rates for patients with advanced stages of NSCLC are low.
Biopharmaceutical company AstraZeneca and its biologics research arm MedImmune Friday jointly announced the receipt of approval from the US Food and Drug Administration (FDA) for IMFINZI (durvalumab) for the treatment of patients with unresectable
Stage III non-small cell lung cancer (NSCLC).
sup] Notably, only 20% of patients with stage IV colon cancer with unresectable
synchronous liver-only-metastases (CLM) present with resectable lesions at diagnosis.
Pembrolizumab was first approved in 2014 for the treatment of patients with unresectable
or metastatic melanoma and disease progression following ipilimumab and, if the patients were positive for the BRAF V600 mutation, a BRAF inhibitor.
Dabrafenib and trametinib are the third and fourth drugs to be approved by the FDA for metastatic or unresectable
melanoma since 2011, when vemurafenib (Zelboraf) and ipilimumab (Yervoy) were approved.
Given the demonstrated benefit of adding chemotherapy to radiotherapy, concomitant CRT is currently the standard of care for people with unresectable
HNCs, provided no contraindication towards such aggressive management of the disease exists.
Rescue Surgery for unresectable
colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.
Currently, there are no approved maintenance therapies for patients responding to first-line treatment for unresectable
stage III NSCLC.
The possibility that RFA prolongs survival in patients with unresectable
hepatocellular carcinoma is exciting, because fewer than 30% of such patients are candidates for surgical resection, he said.
Mayer of the Dana-FarberCancer Institute in Boston says the procedure is "a promising technique that will probably prolong survival in patients who are unresectable
[can't have their tumors cut out].
EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that the Phase III START(a) trial of its investigational product L-BLP25 (formerly referred to as Stimuvax([R])) in patients with unresectable
, locally advanced stage IIIA or IIIB non-small cell lung cancer (NSCLC) did not meet its primary endpoint to demonstrate a statistically significant improvement in overall survival (OS).
AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has approved Imfinzi for the treatment of patients with unresectable
Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT).